TipRanks
Go Ultimate55% OFF

Compare RemeGen Co. Ltd. Class H (REGMF) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
REGMFRemeGen Co. Ltd. Class H$8.31$6.60B7.89-22.78%Strong BuyUnlock the REGMF analyst price target with TipRanks PremiumREGMFUnlock the REGMF top-analyst price target with TipRanks Premium
HK:9926Akeso, Inc.HKD 78.90HKD 76.70B-66.36-26.51%Strong BuyUnlock the HK:9926 analyst price target with TipRanks PremiumREGMF vs HK:9926Unlock the HK:9926 top-analyst price target with TipRanks Premium
HK:9966Alphamab OncologyHKD 6.08HKD 6.06B-30.61-45.77%―Unlock the HK:9966 analyst price target with TipRanks PremiumREGMF vs HK:9966Unlock the HK:9966 top-analyst price target with TipRanks Premium
HK:9969InnoCare Pharma Ltd.HKD 11.25HKD 16.81B12.39-18.42%Strong BuyUnlock the HK:9969 analyst price target with TipRanks PremiumREGMF vs HK:9969Unlock the HK:9969 top-analyst price target with TipRanks Premium
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class HHKD 15.39HKD 30.07B-69.15-39.11%Moderate BuyUnlock the HK:1877 analyst price target with TipRanks PremiumREGMF vs HK:1877Unlock the HK:1877 top-analyst price target with TipRanks Premium
HK:2696Shanghai Henlius Biotech, Inc. Class HHKD 47.76HKD 26.75B26.13-25.78%Strong BuyUnlock the HK:2696 analyst price target with TipRanks PremiumREGMF vs HK:2696Unlock the HK:2696 top-analyst price target with TipRanks Premium

Performance Comparison

-60%-40%-20%0%20%40%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
REGMFRemeGen Co. Ltd. Class H8.30-3.67-30.62%
HK:9926Akeso, Inc.81.50-36.80-31.11%
HK:9966Alphamab Oncology6.21-5.46-46.79%
HK:9969InnoCare Pharma Ltd.11.25-3.37-23.05%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H15.26-11.44-42.85%
HK:2696Shanghai Henlius Biotech, Inc. Class H49.06-20.04-29.00%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts